Heilongjiang Dino Pharmaceutical

Heilongjiang Dino Pharmaceutical is a Chinese pharmaceutical company headquartered in Harbin, specializing in the development and production of chemical drugs and traditional Chinese medicines. The company is widely recognized for its gastrointestinal health products, particularly its colloidal bismuth pectin formulations marketed under the Dino brand for the treatment of peptic ulcers and chronic gastritis. Beyond gastroenterology, its product portfolio includes treatments for cardiovascular diseases, respiratory infections, and endocrine disorders. Heilongjiang Dino Pharmaceutical operates modern manufacturing facilities that adhere to national Good Manufacturing Practice (GMP) standards. The company has historically been active on the National Equities Exchange and Quotations (NEEQ) in China, reflecting its established position in the regional pharmaceutical market. Its business model focuses on providing high-quality, affordable generic medications to the Chinese domestic healthcare sector.